The company's microfluidic platform allows for efficient delivery of gene-editing molecules into human cells, which can be used to treat various disorders. This technology enables the development of new cell therapies that were previously inaccessible and accelerates the commercialization of existing cell therapies by reducing cost, complexity, and processing time while improving efficacy and safety.